Filing Details

Accession Number:
0000899243-23-020082
Form Type:
4
Zero Holdings:
No
Publication Time:
2023-10-31 21:43:04
Reporting Period:
2023-10-27
Accepted Time:
2023-10-31 21:43:04
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1609809 Seres Therapeutics Inc. MCRB Pharmaceutical Preparations (2834) 274326290
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1744682 Paula Cloghessy C/O Seres Therapeutics, Inc.
200 Sidney Street
Cambridge 02139
See Remarks No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2023-10-27 9,418 $0.00 48,588 No 4 M Direct
Common Stock Disposition 2023-10-30 2,904 $1.35 45,684 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Restricted Stock Units Acquisiton 2023-04-27 18,835 $0.00 18,835 $0.00
Common Stock Restricted Stock Units Disposition 2023-10-27 9,418 $0.00 9,418 $0.00
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
18,835 No 4 A Direct
9,417 No 4 M Direct
Footnotes
  1. On February 3, 2023, the reporting person was granted an award of 18,835 restricted stock units ("RSUs"), which vest in the form of shares of the Issuer's common stock in two substantially equal installments upon the satisfaction of certain performance criteria. On April 27, 2023 (the "Initial Milestone Date"), the Issuer's Administrator determined that the performance criteria for the first installment were met, resulting in the vesting and settlement of the award as to 9,418 RSUs on October 27, 2023, the date that was six months from the Initial Milestone Date. The remaining 9,417 RSUs shall vest on October 27, 2024, the date that is eighteen months from the Initial Milestone Date.
  2. Includes 7,424 shares of common stock acquired under the Issuer's employee stock purchase plan.
  3. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 instruction adopted by the reporting person on March 17, 2023, solely with the intent to cover taxes in connection with the vesting of the RSUs.
  4. The price reported in column 4 is a weighted average of the price. These shares were sold in multiple transactions at prices ranging from $1.35 to $1.3614, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  5. Each RSU represents a contingent right to receive one share of Issuer common stock. The RSUs do not have an expiration date.